1. Ototoxicity prevention during the SARS-CoV-2 (COVID-19) emergency.
- Author
-
Ciorba A, Skarżyński PH, Pelucchi S, and Hatzopoulos S
- Subjects
- Antiviral Agents therapeutic use, Chloroquine therapeutic use, Chloroquine toxicity, Humans, Hydroxychloroquine therapeutic use, Pandemics prevention & control, Risk Assessment, SARS-CoV-2 drug effects, Antiviral Agents adverse effects, Chloroquine adverse effects, Hydroxychloroquine adverse effects, Ototoxicity prevention & control, Ototoxicity virology, COVID-19 Drug Treatment
- Abstract
Aim of this paper is to remind the risk of ototoxicity when using chloroquine and hydroxychloroquine, in particular as prophylactic agents against SARS-CoV-2, during the pandemic. Healthy subjects taking chloroquine and hydroxychloroquine as prophylactic agents against SARS-CoV-2, during the pandemic, should be screened periodically, at least by Otoacoustic Emissions (OAEs) in order to detect early manifestations of possible cochlear ototoxic damages., (Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF